Asylia Announces Formation of Distinguished Scientific Advisory Board
HOUSTON, July 22, 2021 – Asylia Therapeutics (“Asylia”), a development-stage biotechnology company advancing novel
July 22, 2021
Immunity
Matters!
Immunity
Immunity
Matters!
Promise for Patients
Asylia Therapeutics is a private development stage biotechnology company committed to transforming scientific advances into safe and effective medicines for cancer and auto-immune diseases. Asylia’s platform centers on a drug pipeline capable of modulating antigen presentation to the immune system which has produced unprecedented anti-tumor responses across multiple cancer models.
Promise for Patients
Asylia Therapeutics is a private development stage biotechnology company committed to transforming scientific advances into safe and effective medicines for cancer and auto-immune diseases. Asylia’s platform centers on a drug pipeline capable of modulating antigen presentation to the immune system which has produced unprecedented anti-tumor responses across multiple cancer models.
Video created by life-science-animation.com
ASY-77A: Unlocking Immune Recognition of Tumor Antigens
ASY-77A binds ADP-HSP70, a stress-induced chaperone uniquely exposed on tumor cells and loaded with tumor-derived antigens. By forming immune complexes and engaging activating Fcγ receptors, ASY-77A drives antigen presentation and primes anti-tumor T cell responses — transforming tumor stress into a precise immune activation signal.
In the News
Stay up to date with the latest news from Asylia Therapeutics
Asylia Therapeutics, Inc. Announces Closing of $14.5 Million Series A Financing
Proceeds will support development of novel antibody drugs that convert immunologically “cold” tumors into
May 25, 2021
JLABS @ TMC and Asylia Therapeutics on Navigating a Powerful Tool: The Human Immune System
Houston, Texas. February 8, 2021 – Houston: the true third coast of innovation. Texas
February 8, 2021
In the News
Stay up to date with the latest news from Asylia Therapeutics
Asylia Announces Formation of Distinguished Scientific Advisory Board
HOUSTON, July 22, 2021 – Asylia Therapeutics (“Asylia”), a development-stage biotechnology company advancing novel
July 22, 2021
Asylia Therapeutics, Inc. Announces Closing of $14.5 Million Series A Financing
Proceeds will support development of novel antibody drugs that convert immunologically “cold” tumors into
May 25, 2021
JLABS @ TMC and Asylia Therapeutics on Navigating a Powerful Tool: The Human Immune System
Houston, Texas. February 8, 2021 – Houston: the true third coast of innovation. Texas
February 8, 2021
